2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1422

Pain after Total Knee Arthroplasty: Poverty Modifies the Effect of Race and Education
Abstract Number: 1423

Racial Disparities in Pain and Function after Total Knee Arthroplasty in the United States: A Systematic Literature Review
Abstract Number: 1424

Barriers to Primary Care Clinician Adherence to Clinical Guidelines for the Management of Low Back Pain: A Systematic Review and Meta-Synthesis of Qualitative Studies
Abstract Number: 1425

Current Tobacco Use and the Rates of Complications after Total Hip Arthroplasty
Abstract Number: 1426

The Effect of Anti-Interleukin-6 Receptor Antibody in Ovariectomized Mice
Abstract Number: 1427

Analgesic Effects of the Novel Alpha-2-Delta Ligand Mirogabalin (DS-5565) in Experimental Animal Models of Fibromyalgia
Abstract Number: 1428

Subchondral Bone Structure and Pain Behaviors in Complete Freund’s Adjuvant (CFA) Monoarthritis in Mice Treated with Intra-Articular (IA) Neurotoxin
Abstract Number: 1429

The Effect of Gabapentin and Cyclooxygenase Inhibitors on Evoked and Ongoing Pain-like Behavior in Two Arthritis Models in Mice
Abstract Number: 1430

Peripheral HMGB1 Regulates Arthrtis-Associated Pain-like Behaviour
Abstract Number: 1431

Age and Sex Impacts the Development of Hypersensitivity in the Murine Partial Medial Menisectomy Model of Osteoarthritis
Abstract Number: 1432

Relationship Between Patient Reported Outcome Measures and Evoked Pain Measures in Knee Osteoarthritis
Abstract Number: 1433

Predicting Response to Osteoarthritis Treatment Based on Patient Reported Outcome Measures and Quantitative Sensory Testing
Abstract Number: 1434

Neuropathic Pain in Patients with Rheumatoid Arthritis: Relation with Clinical Variables
Abstract Number: 1435

Central Pain Sensitization in Rheumatoid Arthritis – Role of ACPA?
Abstract Number: 1436

Characterization of Patient Reported Pain Medication in Early Vs. Established Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].